Identifying implications of thrombolysis for stroke rehabilitation: Knowledge gaps in current research

Disability and Rehabilitation

Volumn 35, Issue 11, 2013, Pages 924-930

  Finch, Emma ^a,b,c   Hayward, Kathryn S ^a   Fleming, Jennifer ^a,b,c   Copland, David A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c QUEENSLAND HEALTH   (Australia)

Author keywords

Allied health; Outcomes; Rehabilitation; Review; RtPA; Stroke; Thrombolysis

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

AGE; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC THERAPY; HUMAN; METHODOLOGY; REVIEW; TIME; TREATMENT OUTCOME;

AGE FACTORS; FIBRINOLYTIC AGENTS; HUMANS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84877103627     PISSN: 09638288     EISSN: 14645165     Source Type: Journal    
DOI: 10.3109/09638288.2012.726315     Document Type: Article

References (54)

1. Baldwin K, Orr S, Briand M, Piazza C, Veydt A, McCoy S. Acute isch-emic stroke update. Pharmacotherapy 2010;30:493-514.
2. National Stroke Foundation. Facts fgures and statistics. 2010 [23 August 2010]; Available from: www.strokefoundation.com.au/facts-fgures-and-stats
3. World Health Organisation. Global burden of stroke. In Te Atlas of Heart Disease and Stroke. 2004 [accessed 15 December 2011]; Available from: www.who.int/cardiovascular-disease/en/cvd-atlas-15-burden- stroke.pdf
4. Williams M, Patil S, Toledo EG, Vannemreddy P. Management of acute ischemic stroke: current status of pharmacological and mechanical endovascular methods. Neurol Res 2009;31:807-815.
5. Donnan GA, Davis SM, Parsons MW, Ma H, Dewey HM, Howells DW. How to make better use of thrombolytic therapy in acute ischemic stroke. Nat Rev Neurol 2011;7:400-409.
6. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Trombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009;4:CD000213.
7. Brott T, Adams HP Jr, Olinger C P, Marler JR, Barsan WG, Biller J, Spilker J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864-870.
8. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607.
9. Mahoney FI, Barthel DW. Functional evaluation: the barthel index. Md State Med J 1965;14:61-65.
10. Barber PA, Parsons MW, Desmond PM, Bennett DA, Donnan GA, Tress BM, Davis SM. Te use of PWI and DWI measures in the design of "proof-of- concept" stroke trials. J Neuroimaging 2004;14:123-132.
11. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008;371:1612-1623.
12. Stemer A, Lyden P. Evolution of the thrombolytic treatment window for acute ischemic stroke. Curr Neurol Neurosci Rep 2010;10:29-33.
13. National Institute of Neurological Disorders and Stroke. Tissue plas-minogen activator for acute ischemic stroke. Te New England Journal of Medicine. 1995;333:1581-1587.
14. Fagan SC. Stroke: Measuring disease-free life afer thrombolysis. Nat Rev Neurol 2010;6:361-362.
15. Davis SM, Donnan GA, Butcher KS, Parsons M. Selection of thrombo-lytic therapy beyond 3 h using magnetic resonance imaging. Curr Opin Neurol 2005;18:47-52.
16. Davis SM, Donnan GA, Parsons M W, Levi C, Butcher KS, Peeters A, Barber PA, et al.; EPITHET investigators. Efects of alteplase beyond 3 h afer stroke in the Echoplanar Imaging Trombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008;7:299-309.
17. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Te Lancet 2008;352:1245-1251.
18. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, et al.; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-1703.
19. Hacke W, Kaste M, Fieschi C, Von Krummer R, Davalos A, Meier C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intraveneous alteplase in acute ischemic stroke (ECASS II). Te Lancet 1998;352:1245-1251.
20. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours afer symptom onset. Te ATLANTIS Study: a randomized controlled trial. Alteplase Trombolysis for Acute Noninterventional Terapy in Ischemic Stroke. JAMA 1999;282:2019-2026.
21. Hacke W, Kaste M, Fieschi C, Toni D, Lesafre E, von Kummer R, Boysen G, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. Te European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
22. Clark WM, Albers GW, Madden K P, Hamilton S. Te rtPA (alteplase) 0-to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Tromblytic therapy in acute ischemic stroke study investigators. Stroke 2000;31:811-816.
23. Albers G W, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000;283:1145-1150.
24. Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, Shinohara Y, Yamaguchi T; J-MARS Investigators. Trombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010;41:1984-1989.
25. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, Hennerici MG, et al.; SITS-MOST investigators. Trombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Trombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-282.
26. Shobha N, Buchan AM, Hill MD; Canadian Alteplase for Stroke Efectiveness Study (CASES). Trombolysis at 3-4.5 hours afer acute ischemic stroke onset-evidence from the Canadian Alteplase for Stroke Efectiveness Study (CASES) registry. Cerebrovasc Dis 2011;31:223-228.
27. Roth EJ, Heinemann AW, Lovell LL, Harvey RL, McGuire JR, Diaz S. Impairment and disability: their relation during stroke rehabilitation. Arch Phys Med Rehabil 1998;79:329-335.
28. Glymour MM, Berkman LF, Ertel KA, Fay ME, Glass TA, Furie KL. Lesion characteristics, NIH stroke scale, and functional recovery afer stroke. Am J Phys Med Rehabil 2007;86:725-733.
29. Balu S. Diferences in psychometric properties, cut-of scores, and outcomes between the Barthel Index and Modifed Rankin Scale in phar-macotherapy-based stroke trials: systematic literature review. Curr Med Res Opin 2009;25:1329-1341.
30. Quinn TJ, Langhorne P, Stott DJ. Barthel index for stroke trials: development, properties, and application. Stroke 2011;42:1146-1151.
31. Hsieh Y W, Wang CH, Wu SC, Chen PC, Sheu CF, Hsieh CL. Establishing the minimal clinically important diference of the Barthel Index in stroke patients. Neurorehabil Neural Repair 2007;21:233-238.
32. Aggarwal NT, Schneider JA, Wilson RS, Beck TL, Evans DA, Carli CD. Characteristics of MR infarcts associated with dementia and cognitive function in the elderly. Neuroepidemiology 2012;38:41-47.
33. Ferguson C. Use of thrombolysis in acute ischaemic stroke. Emergency Medicine Journal. 2010;27:245.
34. Bruno A, Switzer JA, Durkalski VL, Nichols FT. Is a prestroke modifed Rankin Scale sensible? Int J Stroke 2011;6:414-415.
35. Quinn TJ, Dawson J, Walters MR, Lees KR. Exploring the reliability of the modifed rankin scale. Stroke 2009;40:762-766.
36. Quinn TJ, Dawson J, Walters MR, Lees KR. Reliability of the modifed Rankin Scale: a systematic review. Stroke 2009;40:3393-3395.
37. Saver JL. Optimal end points for acute stroke therapy trials: best ways to measure treatment efects of drugs and devices. Stroke 2011;42:2356-2362.
38. Meyer M, Murie-Fernandez M, Hall R, Liu Y, Fang J, Salter K, Foley N, Teasell R. Assessing the impact of thrombolysis on progress through inpatient rehabilitation afer stroke: a multivariable approach. Int J Stroke 2012;7:460-464.
39. Wagle J, Farner L, Flekkøy K, Bruun Wyller T, Sandvik L, Fure B, Stensrød B, Engedal K. Early post-stroke cognition in stroke rehabilitation patients predicts functional outcome at 13 months. Dement Geriatr Cogn Disord 2011;31:379-387.
40. Gadidi V, Katz-Leurer M, Carmeli E, Bornstein NM. Long-term outcome poststroke: predictors of activity limitation and participation restriction. Arch Phys Med Rehabil 2011;92:1802-1808.
41. Gunaydin R, Karatepe AG, Kaya T, Ulutas O. Determinants of quality of life (QoL) in elderly stroke patients: a short-term follow-up study. Arch Gerontol Geriatr 2011;53:19-23.
42. Haley WE, Roth DL, Kissela B, Perkins M, Howard G. Quality of life afer stroke: a prospective longitudinal study. Qual Life Res 2011;20:799-806.
43. Leach MJ, Gall SL, Dewey HM, Macdonell RA, Trif AG. Factors associated with quality of life in 7-year survivors of stroke. J Neurol Neurosurg Psychiatr 2011;82:1365-1371.
44. Boosman H, Schepers VP, Post M W, Visser-Meily JM. Social activity contributes independently to life satisfaction three years post stroke. Clin Rehabil 2011;25:460-467.
45. Graven C, Brock K, Hill K, Joubert L. Are the rehabilitation and/or care co-ordination interventions delivered in the community efective in reducing depression, facilitating participation and improving quality of life afer stroke? Disability and Rehabilitation 2011;33:1501-1520.
46. Derex L, Nighoghossian N. Trombolysis, stroke-unit admission and early rehabilitation in elderly patients. Nat Rev Neurol 2009;5:506-511.
47. Kugler C, Altenhöner T, Lochner P, Ferbert A; Hessian Stroke Data Bank Study Group ASH. Does age infuence early recovery from isch-emic stroke? A study from the Hessian Stroke Data Bank. J Neurol 2003;250:676-681.
48. Delgado MG, Michel P, Naves M, Maeder P, Reichhart M, Wintermark M, Bogousslavsky J. Early profles of clinical evolution afer intravenous thrombolysis in an unselected stroke population. J Neurol Neurosurg Psychiatr 2010;81:282-285.
49. Bodenant M, Leys D, Debette S, Cordonnier C, Dumont F, Hénon H, Girot M, et al. Intravenous thrombolysis for acute cerebral ischaemia: comparison of outcomes between patients treated at working versus nonworking hours. Cerebrovasc Dis 2010;30:148-156.
50. Hemmen TM, Rapp KS, Emond JA, Raman R, Lyden PD. Analysis of the National Institute of Neurological Disorders and Stroke tissue plasminogen activator studies following European Cooperative Acute Stroke Study III patient selection criteria. J Stroke Cerebrovasc Dis 2010;19:290-293.
51. Zhou XY, Wang SS, Collins ML, Davis SM, Yan B. Efcacy and safety of diferent doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke. J Clin Neurosci 2010;17:988-992.
52. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke-background and study protocol. 1985;16:885-890.
53. Jennett B, Bond M. Assessment of outcome afer severe brain damage. Lancet 1975;1:480-484.
54. Duncan P W, Jorgensen HS, Wade DT. Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. Stroke 2000;31:1429-1438.